<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290286</url>
  </required_header>
  <id_info>
    <org_study_id>i2TransHealth</org_study_id>
    <nct_id>NCT04290286</nct_id>
  </id_info>
  <brief_title>i2TransHealth: Interdisciplinary, Internet-based Trans Health Care</brief_title>
  <official_title>Interdisciplinary, Internet-based Trans Health Care (i2TransHealth): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      i2TransHealth is a randomized controlled trial that investigates the outcomes of an&#xD;
      internet-based health care approach for trans persons. As a health services research project,&#xD;
      i2TransHealth aims at reducing the structural disadvantage for trans persons [people with&#xD;
      transsexualism (TS: ICD-10), gender incongruence (GIC: ICD-11) and/or gender dysphoria (GD:&#xD;
      DSM-5)] living in areas lacking specialized transition-related treatment.&#xD;
&#xD;
      Located at the Institute for Sex Research and in cooperation with the Interdisciplinary&#xD;
      Transgender Health Care Center Hamburg (ITHCCH), both University Medical Center&#xD;
      Hamburg-Eppendorf (UKE), i2TransHealth is an innovative intervention including video&#xD;
      consultation and a 1:1 chat with clinical psychologists. By cooperating with the ITHCCH,&#xD;
      general physicians and psychiatrists provide first and local access to the specialized&#xD;
      treatment provided by the UKE.&#xD;
&#xD;
      In the intervention group, the study participants are invited to use the i2TransHealth&#xD;
      e-health platform including a video consultation hour every two weeks and a messenger between&#xD;
      the video-meetings. In addition, they have the opportunity to receive medical support close&#xD;
      to their home by licensed GPs and psychiatrists according to their needs (especially in case&#xD;
      of a somatic or psychosocial crisis). The waiting group participants will be able to go&#xD;
      forward with transition-related care after four months of study participation, either via the&#xD;
      i2TransHealth e-health approach or as part of standard care.&#xD;
&#xD;
      The primary outcome measure is a reduced symptomatology for trans persons (BSCL). Secondary&#xD;
      outcome parameters include quality of life and patient satisfaction as well as&#xD;
      healthcare-related costs and cost-effectiveness. Finally, based on a longitudinal design, it&#xD;
      will be assessed if the physicians improve their trans-related expertise by cooperating&#xD;
      within the i2TransHealth-network.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom burden according to BSI-18</measure>
    <time_frame>Change from Baseline Mental Health Symptoms to the point of time after online intervention (Baseline + 4 months)</time_frame>
    <description>References:&#xD;
Franke, G. H. (2000). Franke, G.H. (2000). BSI. Brief Symptom Inventory - Deutsche Version. Manual. Göttingen: Beltz.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (physical health, psychological health, social relationships, and environment)</measure>
    <time_frame>Change from Baseline QoL to the point of time after online intervention (Baseline + 4 months)]</time_frame>
    <description>QoL is measured using the WHOQOL-BREF (WHO, 1998).&#xD;
References:&#xD;
Angermeyer, M. C., Kilian, R., &amp; Matschinger, H. (2000). WHOQOL - WHOQOL-100 und WHOQOL-BREF. Handbuch für die deutschsprachigen Versionen der WHO Instrumente zur Erfassung von Lebensqualität.&#xD;
WHO (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychological medicine, 28(3), 551-558.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment satisfaction according to modified version ZUF-8</measure>
    <time_frame>Treatment satisfaction at the point of time after online intervention (4 months after admission to studies)</time_frame>
    <description>References:&#xD;
Schmidt, J., Lamprecht, F., &amp; Wittmann, W. W. (1989). Zufriedenheit mit der stationären Versorgung. Entwicklung eines Fragebogens und erste Validitätsuntersuchungen. [Satisfaction with inpatient care: Development of a questionnaire and first validity assessments.]. PPmP: Psychotherapie Psychosomatik Medizinische Psychologie, 39(7), 248-255.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct or indirect costs and productivity losses by persons with TS/GD in comparison to the German general population (via CSSRI)</measure>
    <time_frame>Change from Baseline to the point of time after online intervention (Baseline + 4 months)</time_frame>
    <description>References:&#xD;
Chisholm, D., Knapp, M. R. J., Knudsen, H. C., Amaddeo, F., Gaite, L., Wijngaarden, B. van, &amp; Group, E. S. (2000). Client Socio-Demographic and Service Receipt Inventory - European Version: Development of an instrument for international research: EPSILON Study 5. The British Journal of Psychiatry, 177(S39), s28-s33. https://doi.org/10.1192/bjp.177.39.s28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (via EQ-5D-5L): quality-adjusted life years (QALYs)</measure>
    <time_frame>Change from Baseline to the point of time after online intervention (Baseline + 4 months)</time_frame>
    <description>References:&#xD;
Herdman, M., Gudex, C., Lloyd, A., Janssen, MF., Kind, P., Parkin, D., … Badia, X. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727-1736. https://doi.org/10.1007/s11136-011-9903-x</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge increase of the cooperating physicians on trans health care (via VSE)</measure>
    <time_frame>Change from Baseline to the point of time after study completion (Baseline + 18 months)</time_frame>
    <description>References:&#xD;
Raupach, T., Schiekirka, S., Münscher, C., Beißbarth, T., Himmel, W., Burckhardt, G., &amp; Pukrop, T. (2012). Implementierung und Erprobung eines Lernziel-basierten Evaluationssystems im Studium der Humanmedizin. GMS Zeitschrift für medizinische Ausbildung, 29(3), 1-14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of the cooperating physicians with the support in the i2TransHealth network (via modified version ZUF-8)</measure>
    <time_frame>Satisfaction at the point of time after study completion (18 months)</time_frame>
    <description>References:&#xD;
Schmidt, J., Lamprecht, F., &amp; Wittmann, W. W. (1989). Zufriedenheit mit der stationären Versorgung. Entwicklung eines Fragebogens und erste Validitätsuntersuchungen. [Satisfaction with inpatient care: Development of a questionnaire and first validity assessments.]. PPmP: Psychotherapie Psychosomatik Medizinische Psychologie, 39(7), 248-255.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Gender Dysphoria</condition>
  <condition>Gender Identity Disorder</condition>
  <condition>Transsexualism</condition>
  <condition>Gender Identity</condition>
  <condition>Gender Incongruence</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trans persons (n = 105) receive 4 months of e-health intervention according to the i2TransHealth model of care (intervention group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>waiting group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Trans persons (n = 105) wait 4 months until they are offered online intervention according to the i2TransHealth model of care (waiting group)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>i2TransHealth</intervention_name>
    <description>i2TransHealth: online intervention for trans persons</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Gender different from their assigned sex at birth&#xD;
&#xD;
          -  resident at least 50 km outside Hamburg&#xD;
&#xD;
          -  present themselves with treatment needs (TS/GD) to one of the participating physicians&#xD;
             in the i2TransHealth network, or direct contact with institute and/or e-health&#xD;
             platform&#xD;
&#xD;
          -  receive the suspected diagnosis TS/GD during an initial interview in the UKE&#xD;
&#xD;
          -  can operate the video chat cognitively, verbally and auditory&#xD;
&#xD;
          -  Able to read, speak, and understand German&#xD;
&#xD;
          -  Written informed consent after written and oral information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under 18 years of age&#xD;
&#xD;
          -  Missing informed consent&#xD;
&#xD;
          -  Unable to speak German&#xD;
&#xD;
          -  Indication for inpatient treatment, e.g. due to acute psychotic symptoms (self-report,&#xD;
             Prodromal Questionnaire, PQ-B) or severe depressive symptoms (self-report, BDI-II ≥&#xD;
             29)&#xD;
&#xD;
          -  Acute suicidal tendencies&#xD;
&#xD;
          -  Decrease in intelligence (IQ below 70)&#xD;
&#xD;
          -  Acute drug intoxication&#xD;
&#xD;
          -  Failure to meet technical requirements (no Internet access, lack of IT knowledge)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timo Nieder, PhD ECPS</last_name>
    <phone>+4940 7410 52226</phone>
    <email>t.nieder@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.i2transhealth.de/</url>
    <description>https://www.i2transhealth.de/english-landing-page/</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 26, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>October 7, 2020</last_update_submitted>
  <last_update_submitted_qc>October 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Timo Nieder</investigator_full_name>
    <investigator_title>PI: Timo Nieder, PhD ECPS, Head of Outpatient Unit for Sexual Health and Transgender Care, Institute for Sex Research, Sexual Medicine and Forensic Psychiatry (Co-PI: Arne Dekker, PhD, Peer Briken, MD FECSM Prof))</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gender Dysphoria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

